Effects of Inhaled Nitric Oxide on Sublingual Microcirculation in Patients With Right Ventricular Dysfunction After Cardiac Surgery
NCT07918976, Phase 2, Completed, Southeast University, China
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Inhaled Nitric Oxide on Sublingual Microcirculation in Patients With Right Ventricular Dysfunction After Cardiac Surgery | ClinicalTrials.gov |
| NCT number | NCT07918976 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 60 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Southeast University, China | ClinicalTrials.gov |
| Conditions | Cardiac Surgery Intensive Care Treatment, Pulmonary Hypertension, Right Ventricular (RV) Dysfunction | ClinicalTrials.gov |
| Interventions | Inhaled Nitric Oxide (iNO) use | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | perfused vessel density (PVD) | At enrollment and 2 hours after study drug administration | Perfused vessel density (PVD) is defined as the density of small vessels with actual blood flow per unit tissue area (usually capillaries and small vessels with diameter \<20 μm), obtained noninvasively at the sublingual mucosa using a handheld vital microscope (sidestream dark field, SDF, or incident dark field, IDF) probe. | ClinicalTrials.gov |
| Secondary | Heart rate | At enrollment and 2 hours after study drug administration | ClinicalTrials.gov | |
| Secondary | Mean arterial pressure | At enrollment and 2 hours after study drug administration | ClinicalTrials.gov | |
| Secondary | Central venous pressure | At enrollment and 2 hours after study drug administration | ClinicalTrials.gov | |
| Secondary | Urine output | At enrollment and 2 hours after study drug administration | ClinicalTrials.gov | |
| Secondary | Duration of mechanical ventilation, ICU length of stay and 28-day mortality. | At enrollment and 28 days after study drug administration | ClinicalTrials.gov | |
| Secondary | Tricuspid annular plane systolic excursion (TAPSE) | At enrollment and 28 days after study drug administration | Measures the longitudinal displacement of the tricuspid annulus toward the cardiac apex during systole, obtained by M-mode in the apical 4-chamber view. | ClinicalTrials.gov |
| Secondary | Right ventricular fractional area change (RVFAC) | At enrollment and 28 days after study drug administration | Calculated as: (RV end-diastolic area - RV end-systolic area) / RV end-diastolic area × 100%, by tracing the RV area in the apical 4-chamber view. | ClinicalTrials.gov |
| Secondary | E/e' ratio | At enrollment and 2 hours after study drug administration | This ratio is used to estimate left ventricular filling pressure (LVFP/LVEDP) and grade diastolic dysfunction. | ClinicalTrials.gov |
| Secondary | Pulmonary artery systolic pressure (PASP) | At enrollment and 2 hours after study drug administration | Noninvasively estimated from the peak tricuspid regurgitation (TR) jet velocity: PASP = 4 × (TR velocity)² + estimated right atrial pressure. | ClinicalTrials.gov |
| Secondary | PaO₂/FiO₂ ratio | At enrollment and 2 hours after study drug administration | Arterial oxygen partial pressure divided by the fraction of inspired oxygen | ClinicalTrials.gov |
| Secondary | Lactate | At enrollment and 2 hours after study drug administration | ClinicalTrials.gov | |
| Secondary | Central venous-to-arterial PCO₂ difference (Pcv-aCO₂) | At enrollment and 2 hours after study drug administration | Reflects the adequacy of blood flow (cardiac output) to clear CO₂ produced by tissues-a "flow" marker rather than an oxygenation marker. | ClinicalTrials.gov |
| Secondary | Central venous oxygen saturation (ScvO₂) | At enrollment and 2 hours after study drug administration | Oxygen saturation of blood sampled from the superior vena cava (central venous catheter), reflecting the balance between systemic oxygen delivery (DO₂) and consumption (VO₂). | ClinicalTrials.gov |
| Secondary | Capillary refill time (CRT) | At enrollment and 2 hours after study drug administration | Time for distal capillary bed (e.g., fingertip/knee) to return to baseline color after standardized compression (5 s) - a bedside peripheral/ microcirculatory perfusion marker. | ClinicalTrials.gov |
| Secondary | microvascular flow index (MFI) | At enrollment and 2 hours after study drug administration | A semi-quantitative flow velocity score: the image is divided into 4 quadrants, and the predominant flow type in each quadrant is scored: 0 = no flow 1. = intermittent flow 2. = slow flow 3. = continuous normal flow The final MFI is the mean of the 4 quadrant scores; | ClinicalTrials.gov |
| Secondary | proportion of perfused vessels (PPV) | At enrollment and 2 hours after study drug administration | The percentage of vessels with blood flow out of all vessels: PPV = (number of perfused vessels ÷ total number of vessels) × 100% | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)